BioXcel Therapeutics, Inc. SEC filings BTAIQ
BioXcel Therapeutics, Inc. has 672 filings in SEC EDGAR's recent list, going back to Nov 13, 2017. Its latest annual report, Form 10-K, was filed on Mar 27, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 30, 2026 (acquisition or sale of assets, officer or director change, bylaw or fiscal year change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-K | Annual report | Mar 27, 2026 | Dec 31, 2025 |
| ARS | Annual report to shareholders | Nov 12, 2025 | Dec 31, 2024 |
| 10-K | Annual report | Mar 28, 2025 | Dec 31, 2024 |
| 10-K | Annual report | Mar 22, 2024 | Dec 31, 2023 |
| 10-K/A | Amended annual report | May 1, 2023 | Dec 31, 2022 |
| 10-K | Annual report | Mar 16, 2023 | Dec 31, 2022 |
| 10-K | Annual report | Mar 11, 2022 | Dec 31, 2021 |
| 10-K | Annual report | Mar 12, 2021 | Dec 31, 2020 |
| 10-K | Annual report | Mar 9, 2020 | Dec 31, 2019 |
| 10-K | Annual report | Mar 12, 2019 | Dec 31, 2018 |
Showing 10 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BTAIQ (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New Haven, CT
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1720893
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.